Osteoporosis Testing Market Size & Growth
The Global Osteoporosis Testing Market reached USD 345.22 million in 2025 and is projected to witness lucrative growth by reaching up to USD 541.70 million by 2033 with a CAGR of 4.54 % during forecast period 2026-2033
The osteoporosis testing market is witnessing steady growth driven by the rising global burden of osteoporosis and increasing awareness regarding early diagnosis and fracture prevention. The growing geriatric population, particularly post-menopausal women, is significantly contributing to the demand for routine bone health assessments. Technologies like dual-energy X-ray absorptiometry (DXA) remain the top choice for checking bone mineral density, while new tools like quantitative ultrasound and AI-based imaging are making it easier and faster to diagnose bone health issues. Healthcare providers are increasingly emphasizing preventive screening to reduce long-term healthcare costs associated with osteoporotic fractures. In addition, government initiatives and screening programs are promoting early detection, especially in high-risk populations. The expansion of diagnostic centers and integration of advanced imaging technologies into clinical workflows are further supporting market growth. Continuous innovations focused on portability, accuracy, and cost-effectiveness are expected to drive adoption across both developed and emerging healthcare markets.
Osteoporosis Testing Market Scope
| Metrics | Details |
| CAGR | 4.54 % |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | By Type and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report - Request for Sample
Osteoporosis Testing Market Dynamics
Technological Advancements Lead to the Market’s Growth and are One of the Main Factors Driving the Market Growth.
A variety of technologies have been used to assess skeletal health, the most common of which is dual-energy X-ray absorptiometry (DXA), which measures the spine, hip or entire body. The skeletal health assessment has become faster and more accurate due to recent advances in imaging technology.
For instance, the Hologic, Bedford, MA-based Discovery QDR Series bone densitometer includes High-Definition Instant Vertebral Assessment (IVA), which takes a 10-second scan of the lumbar, thoracic spine to detect vertebral deformities. This allows for classifying more patients as osteoporotic, even if their BMD results are borderline.
A Growing Number of Incidences of Osteoporosis Will Create Opportunities for the Market Players.
The growing number of incidents of osteoporosis is driving the growth of the osteoporosis testing market. Rapid turnaround time and lower cost of procedure over conventional methods also fuel the growth of the osteoporosis testing market. For instance, osteoporosis affects an estimated 75 million people in Europe, North America, and Japan. An increasing number of patients have been visiting for osteoporosis testing, and its growing demand exhibits lucrative growth opportunities for companies investing in this market.
Limitations Associated With Osteoporosis Testing are Factors Hindering the Market Growth.
A DXA test cannot predict who will fracture. DXA is of limited use in people with a spinal deformity or those who have had previous spinal surgery, despite its effectiveness in measuring bone density. One of the major drawbacks of DXA is that there is currently no standardization in bone and soft tissue measurements. There are significant differences in measurements obtained on instruments from the three major DXA machine manufacturers.
Moreover, high cost is also expected to hamper market growth. For instance, the cost of the DXA instrument, which is likely to exceed $100,000, accounts for the majority of the costs associated with its use. Although DXA is better suited to lab-based research rather than field testing.
Osteoporosis Testing Market Segmentation Analysis
The global osteoporosis testing market is segmented based on type, end user and region.
The X-ray Scan Segment Will be Dominated by Market Players During the Forecast Period.
X-ray scans accounted for the highest market stake accounting for approximately 59.7% of the osteoporosis testing market in 2022. X-ray is very helpful and crucial in the diagnosis of osteoporosis. The key X-ray finding indicative of osteoporosis is the loss of bone mass. The main loss is found in the bony trabecula rather than the cortex. The common bones observed for osteoporosis are the lumbar vertebrae, femoral neck and calcaneus.
All X-ray methods offer a bone mineral density (BMD) measure. Still, it has been illustrated that other structural outlooks of the bone are crucial in evaluating fracture risk, like elastic properties and mechanical features, which cannot be determined with densitometry techniques.
There are various techniques used for osteoporosis, including dual X-ray absorptiometry scans, quantitative computed tomography scans and morphometry. Among the commonly utilized techniques, dual X-ray absorptiometry (DXA) is currently the “gold standard” for fracture risk prediction and osteoporosis diagnosis.
Global Osteoporosis Testing Market Geographical Share
North America is the Dominating Region During the Forecast Period.
North America captured approximately 38.5% of the overall market. The most prevalent bone disease, osteoporosis, which affects roughly 10 million people in the United States alone, causes bones to become weak and prone to fractures. The disease is especially common in women, with nearly 20% of women over age 50 having osteoporosis and over half exhibiting the precursor condition of low bone mass.
Each year, osteoporosis-related fractures account for 432,000 hospital admissions and 180,000 nursing home admissions. Given the aging population in the U.S., annual direct costs from osteoporosis are expected to reach approximately $25.3 billion by 2025.
Osteoporosis Testing Market Companies
The major global players include Hologic, Inc., GE HealthCare Technologies Inc., FUJIFILM Holdings Corporation, DMS Imaging SA, Echolight S.p.A., OSTEOSYS Co., Ltd., BeamMed Ltd., Swissray International, Inc., Hitachi, Ltd., Trivitron Healthcare Pvt. Ltd. among others.
Artificial Intelligence Impact Analysis
AI has a significant impact on the overall osteoporosis testing market as new techniques are getting developed. For instance, according to a study in radiology artificial intelligence by the Radiological Society of North America it was found that a new method that combines imaging information with AI can diagnose osteoporosis from hip X-rays.
The Geneva-based Medimaps group has also developed a spine segmentation (SpS) deep learning algorithm, which can enhance and improve the diagnosis and monitoring of osteoporosis.
Key Developments in the Osteoporosis Testing Market
August 2026: Entera Bio reported continued advancement of EB613, its oral PTH(1-34) anabolic tablet for postmenopausal osteoporosis, following FDA alignment on a 12-month registrational Phase 3 study. The program is designed around total hip bone mineral density (BMD) measurement, with Phase 3 initiation planned for late 2026.
- June 2026: Entera Bio received positive FDA feedback supporting its registrational Phase 3 protocol for EB613, including a single randomized, double-blind, placebo-controlled study in approximately 750 postmenopausal women. The development highlights continued innovation around BMD-based endpoints and advanced osteoporosis assessment in clinical development.
- May 2026: Boots and Bone Index Finland launched a pilot Bone Density Scan Service at selected Boots pharmacies using Bindex pulse-echo ultrasound technology. The radiation-free technology enables a rapid bone-health assessment and supports earlier identification of individuals at risk of osteoporosis.
- March 2026: Entera Bio submitted a streamlined Phase 3 protocol for its next-generation single-tablet EB613 formulation, replacing the previous multi-tablet candidate. The revised development program uses total hip BMD as the primary endpoint at 12 months, supported by an open-label extension study.
- March 2026: NHS England and the UK Department of Health and Social Care announced the rollout of 20 additional DEXA scanners across England to expand access to earlier osteoporosis diagnosis. The investment aims to increase bone-density testing capacity and reduce diagnostic waiting times using advanced dual-energy X-ray absorptiometry technology.
Why Choose DataM?
- Technological Innovations: Explores advancements in osteoporosis testing technologies, including dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT), peripheral bone densitometry, vertebral fracture assessment, trabecular bone score (TBS), and emerging digital and AI-supported approaches that support improved assessment of bone mineral density and fracture risk.
- Product Performance & Market Positioning: Evaluates osteoporosis testing solutions based on critical parameters such as measurement accuracy, precision, reproducibility, radiation exposure, scan time, ease of use, clinical workflow integration, anatomical assessment capabilities, and compatibility with fracture-risk evaluation, highlighting how diagnostic providers differentiate through technology, accessibility, and clinical utility.
- Real-World Evidence: Highlights the use of osteoporosis testing across hospitals, diagnostic imaging centers, specialty clinics, and preventive healthcare settings, supporting the identification of low bone density and osteoporosis, fracture-risk assessment, treatment monitoring, and long-term bone health management.
- Market Updates & Industry Changes: Tracks key developments such as advancements in bone densitometry systems, improvements in imaging and fracture assessment technologies, software enhancements, clinical research related to osteoporosis diagnosis, expansion of screening initiatives, and evolving diagnostic practices across major healthcare markets.
- Competitive Strategies: Analyzes how leading companies strengthen their market position through product innovation, expansion of diagnostic portfolios, software and imaging technology development, strategic collaborations, healthcare partnerships, and geographic expansion to address the growing need for bone health assessment and osteoporosis management.
- Pricing & Market Access: Explains pricing variations based on testing technology, equipment configuration, software capabilities, service and maintenance requirements, and healthcare infrastructure, along with market access through hospitals, diagnostic laboratories, imaging centers, specialty clinics, and medical equipment distributors.
- Market Entry & Expansion: Identifies growth opportunities driven by population aging, increasing prevalence of osteoporosis and fragility fractures, greater awareness of early diagnosis, expanding preventive healthcare initiatives, and increasing demand for fracture-risk assessment, while outlining strategies such as technology differentiation, expansion of diagnostic access, healthcare partnerships, and entry into emerging healthcare markets.
The Global Osteoporosis Testing Market Report Would Provide Approximately 92 Tables, 108 Figures and 195 Pages.
Target Audience
- Hospitals & Healthcare Providers
- Diagnostic Imaging Centers
- Orthopedic & Specialty Clinics
- Endocrinology & Rheumatology Practices
- Bone Densitometry & Medical Imaging Equipment Manufacturers
- Diagnostic Technology & Healthcare Software Providers
- Medical Device Distributors & Suppliers
